SYDNEY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ) today announced that Dustin Haines, Chief Executive Officer, will present live at Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on 11th December. Presentation DetailsEvent: Life Sciences Virtual Investor ForumDate: Thursday, 11th December Time: 11:30 AM ETWebcast: REGISTER HERE Recent Company Highlights FDA-approved solution EchoSolv AS continued to bui ...

Core Viewpoint - Echo IQ Limited has successfully completed clinical validation for its heart failure clinical decision support software, EchoSolv HF, in collaboration with the Mayo Clinic Platform, marking a significant milestone towards FDA clearance [1][3][9]. Company Summary - Echo IQ Limited is an AI and medical technology company based in Sydney, Australia, focused on improving decision-making in cardiology through AI-driven technology and proprietary software [11]. - The company is preparing to submit for FDA clearance of EchoSolv HF via the 510(k) regulatory pathway, with submission expected in the coming weeks [4][9]. Clinical Validation Details - The clinical validation assessed EchoSolv HF's ability to detect heart failure using an independent dataset of approximately 17,000 echocardiogram studies, achieving a sensitivity of 99.5% and specificity of 91.0% [2][3][8]. - Completion of this validation fulfills the final clinical requirement before the formal FDA submission [3][8]. Market Opportunity - Heart failure is a leading cause of rehospitalization in the US, accounting for 17% of all healthcare expenditure, with a total market size estimated at US$60 billion [5][8]. - It is projected that one in four Americans will develop heart failure in their lifetime, indicating a significant market opportunity for EchoSolv HF [5][8]. Future Plans - Following potential FDA clearance, the company plans to leverage its existing presence in the US market to promote the uptake of EchoSolv HF [6][8]. - A webinar is scheduled for November 26, 2025, where the CEO will discuss the development and progress in the US market [7][9].

Core Insights - OneMedNet Corporation has significantly expanded its iRWD™ network, enhancing its position as one of the largest live Real-World Data networks globally [1][2] - The company is experiencing momentum in its subscription model, which is crucial for capturing a share of the $60 billion Real-World Evidence market [2][3] Company Expansion - Approximately 380 new provider sites have been added, bringing the total to over 2,130, representing a 22% increase in network scale [6] - Unique de-identified patient records have increased by 13 million, totaling over 47 million, which is a 38% growth [6] - Clinical exams and images have expanded by 50 million, now exceeding 186 million, marking a 37% increase [6] Market Position - OneMedNet's subscription offerings are attracting pharmaceutical, life-science, and AI customers, leading to a virtuous cycle of increased commitments from existing subscribers and new long-term partnerships [2][3] - The company aims to leverage its extensive network to provide precise, diverse, and longitudinal cohorts, enhancing the value of its data feeds [2][3]

Core Insights - Halberd Corporation is collaborating with Mississippi State University to develop a nasal spray treatment for Traumatic Brain Injury (TBI) and is seeking government funding for advanced animal research [1][3]. Group 1: Product Development - The nasal spray treatment is designed for immediate use following head trauma, aiming to mitigate negative effects associated with TBI [2]. - The planned Phase-2 animal research will assess the efficacy of the nasal spray in reducing biochemical changes and behavioral deficits caused by TBI from various sources [3]. - Previous Phase-1 testing indicated that animals receiving the nasal spray showed reduced markers of TBI-induced damage compared to those that did not [3]. Group 2: Technological Integration - The Phase-2 tests will utilize Artificial Intelligence capabilities from Halberd's acquisition of NeuroSense AI to enhance research outcomes [4]. - NeuroSense AI aims to transform preclinical TBI research through multi-modal behavioral analysis and advanced AI interpretation [6]. Group 3: Market Potential - The nasal spray could provide significant advantages for the military by enabling expedited return-to-duty for personnel following head trauma or anxiety conditions [4]. - Halberd Corporation is also exploring private investment and potential corporate restructuring to support its initiatives [5].

Market Overview - The American stock markets have experienced a downturn due to international tariff fears, impacting most sectors, while healthcare stocks have outperformed the general market in 2025 [1] Healthcare Sector Performance - Healthcare stocks are rising above competitors, with some appreciating by at least 30% this year, and smaller stocks seeing increases of 50% or more, indicating potential undervaluation [2] - Royalty Pharma has seen a 25% year-to-date price appreciation, with a current price of $31.37 and a 12-month price forecast of $41.60, suggesting a 32.61% upside [2][4] - CVS Health has experienced a 50% increase in share price since the beginning of the year, with a current price of $67.13 and a 12-month price forecast of $70.41, indicating a 4.89% upside [5][6] - Tempus AI has seen a 60% increase in share price year-to-date, with a current price of $47.83 and a 12-month price forecast of $61.18, suggesting a 27.92% upside [8][9] - Guardant Health's share prices have risen nearly 50% since the beginning of the year, with a current price of $43.14 and a 12-month price forecast of $48.95, indicating a 13.47% upside [11][12] Institutional Investments and Analyst Ratings - Royalty Pharma has seen significant institutional buying, with purchases rising to $748 million in Q4 2024 from $177 million in Q3 2024, and maintains a Buy rating from analysts [3] - CVS Health's short interest has fallen by over 12%, indicating increased investor confidence, and it has a Moderate Buy rating from analysts [7] - Tempus AI's quarterly revenue increased by 35.8% year-over-year to $200.7 million, with gross profit rising by 49.7% to $122.1 million, contributing to its positive analyst ratings [9][10] - Guardant Health has a consensus Buy rating from analysts, with actual revenue consistently beating estimates, although its path to profitability remains uncertain [13][14]